Shares in Ultragenyx and Mereo BioPharma have plunged after their drug for osteogenesis imperfecta (OI) or brittle bone ...

Bisphosphonates reduced complex regional pain syndrome pain intensity in the short term but not other time scales.

Bisphosphanates are used primarily for the prevention and treatment of osteoporosis, and are also indicated for osseous complications of malignancy. In addition to their bone resorption properties, ...

Ultragenyx is developing setrusumab in pediatric and young adult patients across OI sub-types I, III and IV with two late-stage studies: the pivotal Phase 2/3 Orbit study and Phase 3 Cosmic study.

Bisphosphonates are medications that used to treat bone loss and are the most common agent to be prescribed for osteoporosis. These drugs can also reduce fracture risk in cases of previous fracture.

May 13, 2011— -- Many doctors are changing the prescribing length of a class of osteoporosis medication known as bisphosphonates after mounting evidence has linked long-term use of the medication ...

Long-term bisphosphonate therapy can change bones at the microscopic level to make them more susceptible to the rare catastrophic transverse breaks known as atypical femoral fractures (AFFs), ...

Please provide your email address to receive an email when new articles are posted on . “Although we observed an increasing number of osteonecrosis of the jaw cases in our daily practice during the ...

Bisphosphonates are prescription drugs that improve bone density. They’re used to treat several conditions associated with bone loss, including osteoporosis, and to reduce the risk of fractures.